Lonza Group AG Stock
Price
Target price
€602.00
€602.00
-0.130%
-0.8
-0.130%
-
28.07.26 / Tradegate
WKN: 928619 / Symbol: LZAGF / Name: Lonza Group / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Lonza Group AG Stock
Lonza Group AG shows a slight decrease today, losing -€0.800 (-0.130%) compared to yesterday.
Pros and Cons of Lonza Group AG in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Lonza Group AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Lonza Group AG | -0.130% | -1.344% | 4.152% | -0.987% | 3.901% | 102.013% | 105.111% |
| Novartis AG | -0.200% | 3.765% | 2.850% | 39.693% | 18.463% | 75.000% | 75.000% |
| Novartis AG ADR | 1.450% | 4.444% | 2.920% | 40.299% | 18.987% | 49.049% | 81.701% |
| Roche Holding AG ADR | 2.770% | 9.868% | 8.981% | 41.493% | 13.132% | 41.447% | 23.850% |
News
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing